Wcs-LS Syrup is a combination pharmaceutical formulation containing Levosalbutamol (1mg/5ml), Ambroxol (30mg/5ml), and Guaifenesin (50mg/5ml), designed for the management of respiratory conditions characterized by bronchospasm, mucus hypersecretion, and productive cough. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides bronchodilation by relaxing the smooth muscles of the airways, thereby alleviating bronchospasm and improving airflow in obstructive pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD). Ambroxol acts as a mucolytic agent, enhancing the clearance of mucus by breaking down the mucopolysaccharide fibers in the respiratory tract secretions, facilitating expectoration. Guaifenesin serves as an expectorant, increasing respiratory tract fluid secretion, which helps in thinning and loosening mucus, making coughs more productive. The synergistic effect of these active ingredients aids in relieving symptoms associated with acute and chronic respiratory tract infections, bronchitis, and other conditions involving excessive mucus production and airway constriction. Wcs-LS Syrup should be administered as per physician’s guidance, with dosage adjusted according to patient age and clinical response. Caution is advised in patients with hypersensitivity to any component, cardiovascular disorders, or hyperthyroidism.